You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events

Article metrics

Article menu
XML
Emerging technologies, pharmacology and therapeutics
Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events

 

Online download statistics by month:

Online download statistics by month: October 2020 to March 2024

AbstractFullPdf
Oct 2020959455
Nov 2020399364201
Dec 202033231483
Jan 202159959484
Feb 202121442122167
Mar 202113041299183
Apr 202111991194155
May 202115261529148
Jun 202113551349138
Jul 202110851083148
Aug 202112211206195
Sep 202110971078130
Oct 202113361323183
Nov 2021910896121
Dec 202115461543120
Jan 202212961291119
Feb 202216461642106
Mar 202218731879142
Apr 20221590156796
May 202216811672109
Jun 202216851662104
Jul 20221357129975
Aug 202215181519101
Sep 20221273125681
Oct 202217171682131
Nov 202214291412102
Dec 20221012100355
Jan 202391089771
Feb 202356354465
Mar 202379878886
Apr 202360559676
May 202351351561
Jul 202340940245
Aug 202333834855
Sep 202335033659
Oct 2023567484112
Nov 202358942067
Dec 202335427645
Jan 202437016658
Feb 202433323458
Mar 2024550413226
Total41474402914416